A form produced by the Financial Services Council for advisers to use when clients want to replace their risk policies is irrelevant, says the president of the Institute of Financial Advisers.

NZX is hoping it’s third time lucky for equity derivatives in New Zealand, its head of business strategy and sales says.

ASB is expecting floating home loan interest rates to reach 6% by March next year.

Gold has recovered from its sudden price drop but is unlikely to increase in value  much further, one expert says.

The findings of a damning report on participants in the British equity markets are even more pertinent when applied to the smaller New Zealand market, a financial services consultant says.

Property investors will soon have to put a dollar value on the cost of replacing their entire portfolios.

Westpac New Zealand wants to be at the forefront of responsible lending in New Zealand, its head of retail banking says.

The Financial Markets Authority's second anniversary passed quite quietly this week. 

Industry participants are giving the Financial Markets Authority a solid pass mark for its first two years of operation.

Fund manager Trilogy is in Australia's Supreme Court today,  asking to take over the management of the LM First Income Mortgage Fund, in place of LM Investment Management.

Customers who previously might have applied for loans from finance companies have been driven to mainstream lenders by a series of high-profile failures, says ANZ.

None of the KiwiSaver funds monitored by Morningstar have experienced negative returns over any of the one-, three- or five-year monitoring periods, which co-head of fund research Chris Douglas says has come as a pleasant surprise.

A recovering financial sector is tempting people back into jobs in the industry, a new survey has shown

RESIMAC’s interest rate specials were meant to run out two months ago, says sales director Adrienne Church.

Fisher Funds has issued an inflation warning to investors.

Partners’ Life’s managing director Naomi Ballantyne  has brushed off suggestions that there is more to the company’s restructure than a slowdown in medical insurance commissions.